Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Expenses (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Operating Expenses for 10 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 6.14% year-over-year to $23.0 million, compared with a TTM value of $90.4 million through Dec 2025, down 6.81%, and an annual FY2025 reading of $90.4 million, down 6.81% over the prior year.
  • Operating Expenses was $23.0 million for Q4 2025 at Zevra Therapeutics, up from $20.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $27.2 million in Q3 2024 and bottomed at $4.2 million in Q3 2021.
  • Average Operating Expenses over 5 years is $16.8 million, with a median of $19.3 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 323.65% in 2022, then plummeted 46.12% in 2023.
  • Year by year, Operating Expenses stood at $5.4 million in 2021, then surged by 108.98% to $11.3 million in 2022, then skyrocketed by 130.07% to $26.1 million in 2023, then fell by 6.14% to $24.5 million in 2024, then decreased by 6.14% to $23.0 million in 2025.
  • Business Quant data shows Operating Expenses for ZVRA at $23.0 million in Q4 2025, $20.4 million in Q3 2025, and $24.2 million in Q2 2025.